| |
March 14-15, 2023 | San Francisco, CA Get an unequaled in-depth examination of partnership strategies, licensing priorities, and ways to avoid everything that can go wrong with your next big deal. Don’t miss out on this unique learning and networking opportunity. Register Now!
|
|
Today's Big NewsDec 16, 2022 |
|
If the clinical supply chain is poorly managed, sponsors can struggle to cope with the complexities, causing issues. This playbook covers keys to identifying the need to implement an eClinical Supply Chain Management platform. Download now.
|
|
| By James Waldron For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria. Now, a number of Big Pharmas want in. |
|
|
|
By James Waldron If Astellas needed further proof that its $1.3 billion oncology bet was worth the price tag, the second successful phase 3 trial in a month should do the trick. |
By James Waldron Eli Lilly has followed in the footsteps of many Big Pharma contemporaries by penning its own $730 million deal with Sosei Heptares to work on new meds that modulate G protein-coupled receptor (GPCR) targets. |
Sponsored by Personalis If you’re in translational research, you know how challenging trial design and regulatory approval can be. See how the NeXT generation of ctDNA analysis is a major asset for improving informed cancer strategies. |
|
This playbook looks at why insolubility is an issue, and the properties that affect solubility, such as the molecule’s structure; its physical attributes (particle size and dissolution rate); its chemical attributes, including compatibility with excipients; and its biological properties. Download now.
|
|
By James Waldron In these financially straitened times, biotechs need to be increasingly ruthless about which programs they can afford to keep funding. For oncology-focused Sonnet BioTherapeutics, that means halting work on a bispecific molecule while seeking partners for two others. |
Sponsored by Danaher Corporation Genomic Medicines could cure the world’s toughest diseases. The Danaher Genomic Medicines Summit convened many of the field’s top leaders to discuss challenges and strategies for creating a world without disease. |
By Max Bayer Synaptogenix had hoped that a phase 2 trial of its advanced Alzheimer's med would be able to compete with some of the largest pharmas in the world. But unfortunately, as with many valiant efforts, the company failed to meaningfully improve symptoms. |
By Teresa Carey This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
By Max Bayer CEO of Roche Pharmaceuticals departs amid executive domino fall. CSL Behring promotes COO to CEO. Nordic Nanovector experiences executive and director exodus. |
By Anastassia Gliadkovskaya As hospitals open specialized centers to treat the condition, parallel efforts to move the needle on long COVID are picking up in the private sector. |
By Conor Hale Anumana has staked a claim on the idea that there is a wealth of data still to be mined from reading into the electrical activity of the heart. |
By Kevin Dunleavy The U.S. Department of Health and Human Services has urged the Supreme Court to shoot down Pfizer's appeal challenging the U.S. Anti-Kickback Statute. The company wants SCOTUS to reconsider a ruling that blocks it from providing rebates to Medicare patients for its pricey heart medications Vyndaqel and Vyndamax. |
By Andrea Park Medtronic laid out the plans to spin off its patient monitoring and respiratory interventions businesses into a combined company in late October. |
By Zoey Becker Gracell Biotechnologies stole the show at the American Society of Hematology 2022 annual meeting, showcasing a 100% tumor response rate for its BCMA-targeted CAR-T therapy. Takeda is betting big on Nimbus Therapeutics’ TYK2 inhibitor. Plus more. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
